Life-Prolonging Phase III Trials in mCRPC
| Trial | Front-line mCRPC |
|---|---|
| TAX 327 | Docetaxel/prednisone vs. mitoxantrone/prednisone (10) |
| SWOG 9916 | Docetaxel plus estramustine vs. mitoxantrone/prednisone (11) |
| IMPACT | Sipuleucel-T vs. nonactivated immune cell control (19) |
| COU-AA-302 | Abiraterone/prednisone vs. placebo/prednisone (13) |
| ALSYMPCA | SOC ± 223Ra (18) |
| PREVAIL | Enzalutamide vs. placebo (15) |
| After docetaxel | |
| TROPIC | Cabazitaxel/prednisone vs. mitoxantrone/prednisone (16) |
| COU-AA- 301 | Abiraterone/prednisone vs. placebo/prednisone (12) |
| AFFIRM | Enzalutamide vs. placebo (14) |
| ALSYMPCA | SOC ± 223Ra (18) |
| After ARPI or ARPI plus docetaxel in HRR mutated subset only | |
| PROfound | Olaparib vs. abiraterone or enzalutamide (20) |
| After ARPI and DOCETAXEL) | |
| CARD | Cabazitaxel vs. abiraterone or enzalutamide (17) |
| VISION | SOC ± PSMA-617 177Lu |
HRR = homologous recombination repair.